本报讯 （记者刘钊）12月25日，中康控股（02361.HK）旗下中康数字科技有限公司（以下简称"中康科技"）正式发布 《2025年度AI实战成果》（以下简称"报告"）。报告显示，AI在医药行业已从"概念试水"全面转向"实战落地"。 截至目前，中康科技已构建起覆盖全产业链的AI服务生态，累计服务行业客户1685家。其中包括了华润三九、阿斯利康、 诺和诺德等182家药企，安徽省肿瘤医院和浙江大学医学院附属第二医院等512家标杆医院，美年健康等426家体检中心，以及 10993家零售药店。 同时，中康科技已为超300万消费者提供AI健康分析服务，赋能1520余名临床医生进行复杂医学诊断，累计惠及重疾患者 近1.2万人。 健康产业全场景落地 数据智能驱动"效能革命" 报告详细披露了中康科技在营销、医疗、药店、健康管理等核心场景的AI落地成果，展示如何利用数据智能解决行业长期 存在的"痛点"。 在营销端，实现ROI的可视化与最大化。中康科技面向产业宣布AI For Marketing实验室成立。这标志着营销正式从"流量 争夺"迈入"信任驱动"的3.0时代，为产业未来增长注入核心动能。 在医疗端，深耕"循证决策"。中康 ...

在药店领域，公司推出药店智能体已服务超过10,993家药店，利用全面的行业数据，公司建立了涵盖运 营洞察、产品、疾病、会员及员工的五大AI智能体矩阵，以及针对"个人、家庭、疾病及用药"的专业 AI，为门店运营赋能。 在健康管理场景，公司建立了涵盖"个人、家庭、病种及用药"的AI智能体矩阵，精准覆盖超过300万用 户，提供个性化健康干预及风险预警，构建包括预防、筛查及干预的全周期管理体系。 中康控股(02361)发布公告，截至本公告日期，公司在AI大模型及AI智能体的商业化应用方面取得显著 进展，AI服务及产品覆盖营销、医疗健康、药店、消费者管理场景，触达"医、药、患"全范围的健康产 业合作网络。 在营销方面，公司已启动"AI营销实验室"，推出"天宫一号.商用智能体"，为182家制药企业提 供"+AI"数智解决方案，赋能企业在多变环境中实现快速响应，高效决策与行动。 在医疗健康方面，公司依托自主研发的"卓睦鸟医疗大模型"，推出了重疾多学科联合会诊智能 体"iMDT"，已服务512家医院，赋能1520余临床医生进行复杂医疗诊断，大幅提升多学科团队(MDT)决 策质量。 本公告的业务数据显示，公司已经成功从数据技术 ...

在健康管理场景，公司建立了涵盖"个人、家庭、病种及用药"的AI智能体矩阵，精准覆盖超过300万用 户，提供个性化健康干预及风险预警，构建包括预防、筛查及干预的全周期管理体系。 智通财经APP讯，中康控股(02361)发布公告，截至本公告日期，公司在AI大模型及AI智能体的商业化 应用方面取得显著进展，AI服务及产品覆盖营销、医疗健康、药店、消费者管理场景，触达"医、药、 患"全范围的健康产业合作网络。 本公告的业务数据显示，公司已经成功从数据技术服务商转型为AI科技服务商，公司将持续优化"数据 +模型+场景+生态"的能力，以成为健康产业首选的AI服务提供商而不懈努力。 在营销方面，公司已启动"AI营销实验室"，推出"天宫一号·商用智能体"，为182家制药企业提 供"+AI"数智解决方案，赋能企业在多变环境中实现快速响应，高效决策与行动。 在医疗健康方面，公司依托自主研发的"卓睦鸟医疗大模型"，推出了重疾多学科联合会诊智能 体"iMDT"，已服务512家医院，赋能1520余临床医生进行复杂医疗诊断，大幅提升多学科团队(MDT)决 策质量。 在药店领域，公司推出药店智能体已服务超过10,993家药店，利用全面的行 ...

格隆汇12月24日丨中康控股(02361.HK)宣布，截至公告日期，公司在AI大模型及AI智能体的商业化应用 方面取得显著进展，AI服务及产品覆盖营销、医疗健康、药店、消费者管理场景，触达「医、药、 患」全范围的健康产业合作网络： 医疗健康 在医疗健康方面，我们依托自主研发的「卓睦鸟医疗大模型」，推出了重疾多学科联合会诊智能体 「iMDT」，已服务512家医院，赋能1,520余临床医生进行复杂医疗诊断，大幅提升多学科团队(MDT) 决策质量。 药店 营销 在营销方面，我们已启动「AI营销实验室」，推出「天宫一号 · 商用智能体」，为182家制药企业提供 「+AI」数智解决方案，赋能企业在多变环境中实现快速响应，高效决策与行动。 在药店领域，我们推出药店智能体已服务超过10,993家药店，利用全面的行业数据，我们建立了涵盖运 营洞察、产品、疾病、会员及员工的五大 AI智能体矩阵，以及针对「个人、家庭、疾病及用药」的专 业AI，为门店运营赋能。 消费者管理 在健康管理场景，我们建立了涵盖「个人、家庭、病种及用药」的AI智能体矩阵，精准覆盖超过300万 用户，提供个性化健康干预及风险预警，构建包括预防、筛查及干预的 ...

Core Insights - Zhongkang Technology's Tiangong-1 platform has recently completed the adaptation of the advanced language model DeepSeek-V3.2-Exp, emphasizing a dual strategy of technological independence and ecological openness [1][2] Group 1: Technology and Innovation - The Tiangong-1 platform serves as the AI application capability hub for the health industry, built on the dual-core driving architecture of the self-developed "Zhuomuniao" medical model and the "Tiangong-1" decision-making model [1] - This unique architecture integrates the professionalism of the medical field with the broad applicability of business decision-making, ensuring Tiangong-1's leading position and professional barriers in the complex health industry [1] Group 2: Ecosystem and Product Offering - The intelligent agent ecosystem of Tiangong-1 is designed as a combination of a "supermarket" and a "factory," providing standardized intelligent agent products that cover the entire spectrum of "medicine, pharmacy, patients, and management" for users to quickly address common issues [2] - The platform also offers powerful intelligent agent creation tools, allowing clients to customize their agents based on unique business processes, thereby securing proprietary intelligent agent assets and enabling continuous evolution of core capabilities [2] - The adaptation of excellent third-party models like DeepSeek-V3.2-Exp significantly enriches the "raw materials" library under the "factory" model, allowing enterprises to freely combine and call upon various models based on specific task performance, cost, and efficiency requirements, achieving a synergistic effect of "1+1>2" [2]

Core Insights - Zhongkang Technology has launched the "Tiangong No.1 Health Industry AI Application Capability Hub," marking a new phase in the intelligent transformation of the health industry [1][4] - The "Zhuomuniao Medical Model," the core engine of the hub, has achieved the top ranking in the "Medical Language Understanding" category on the MedBench evaluation platform, showcasing its leading position in the medical AI field [1][2] Company Overview - Zhongkang Technology has been deeply integrated with the pharmaceutical industry for 18 years, combining advanced AI technology to create significant business value and strategic importance for pharmaceutical companies [1][2] AI Model Capabilities - The "Zhuomuniao Medical Model" has a scale of 70 billion parameters, enabling it to deeply analyze vast amounts of medical literature, clinical guidelines, and drug instructions, thus providing precise understanding and key information extraction [2] - The hub offers a comprehensive AI application ecosystem that empowers individuals, facilitates organizational collaboration, and fosters technological innovation [2] Individual Empowerment - The commercial intelligent agent of Tiangong No.1 provides seven professional capabilities, significantly enhancing the efficiency of pharmaceutical professionals, such as reducing the time to generate evidence reports from weeks to minutes, achieving a sevenfold increase in efficiency [2] Organizational Collaboration - The "Enterprise Growth Workbench" addresses the challenges of multi-department collaboration in pharmaceutical companies, featuring over 100 intelligent agents that enhance departmental efficiency across the entire pharmaceutical marketing chain [3] - This model breaks down departmental barriers and fosters competitive growth through a "single-point breakthrough × collaborative evolution" approach [3] Technical Foundation - The intelligent agent center serves as the technical foundation of the hub, driven by both the "Zhuomuniao Medical Model" and the "Tiangong No.1 Decision Model," integrating comprehensive market data and industry experience [3] - The multi-model collaboration capability allows for effective responses to complex medical tasks, ensuring knowledge freshness and decision relevance [3] Industry Impact - The launch of the hub is not just a technological advancement but also a foundational infrastructure for the intelligentization of the health industry, aiming to redefine work methods and decision-making processes [4] - Zhongkang Technology aspires to be a standard setter and connector in the health industry AI application ecosystem, promoting an open, innovative, and win-win environment [4][5]

Core Insights - The MedBench platform has released its latest evaluation results for 2025, highlighting the "Zhuomuniao Medical Model" from Zhongkang Technology, which ranked 2nd overall and 1st in medical language understanding, showcasing its significant advantages in integrating natural language processing with medical expertise [1] Group 1: Model Performance - The "Zhuomuniao Medical Model" is built on nearly two decades of data accumulation and industry insights from Zhongkang Technology, utilizing a high-quality training resource that includes over one million medical documents, guidelines, textbooks, and drug instructions, as well as tens of millions of de-identified clinical data, disease records, and unstructured medical records [1] - The model has a parameter count of 70 billion, and its performance is enhanced through large-scale pre-training and multi-stage instruction fine-tuning, along with advanced techniques such as data cleaning, deduplication, and augmentation [1] Group 2: Application and Impact - The "Zhuomuniao Medical Model" serves as an intelligent engine that spans the entire health service chain, supporting the "Healthcare Full-Scenario Intelligent Body" launched by Zhongkang Technology in March 2025 [1] - This intelligent body is developed using the Tiangong No. 1 and Zhuomuniao medical platforms, integrating high-quality industry data, professional knowledge, and leading model distillation technology to create intelligent solutions for various scenarios including commercial, medical, pharmacy, health management, and research [1] - These intelligent bodies are designed to achieve a business closed-loop characterized by "intelligent decision-making, agile action, and controllable results," thereby enhancing efficiency and service quality in the healthcare industry [1]

Core Insights - Zhongkang Holdings (02361.HK) has launched the "Tiangong No.1 Health Industry AI Application Capability Hub," which aims to transform the "Zhuomuniao Medical Model" into a driving force for the industry, providing tangible business value and strategic significance for pharmaceutical companies [1][2] - The hub is positioned as the foundational infrastructure for the intelligent health industry, aiming to become a unified entry point and standard setter for AI applications in the health sector, connecting the entire pharmaceutical value chain from research and development to production, distribution, and services [1][2] Company Developments - The "Tiangong No.1 Health Industry AI Application Capability Hub" is based on the "Zhuomuniao Medical Model," which ranks first in the "Medical Language Understanding" assessment on the MedBench platform, attributed to its 70 billion parameters that allow for deep analysis of vast amounts of medical literature [2] - The company emphasizes that the AI industry has moved beyond mere technical competition to a new stage where "application defines value," particularly in the health sector, as highlighted by the State Council's recent directive to promote AI in various healthcare applications [2] Future Outlook - Zhongkang Technology plans to continuously enhance the "Tiangong No.1 Health Industry AI Application Capability Hub" and collaborate with industry peers to explore new paths for AI-enabled marketing, aiming for a comprehensive intelligent upgrade of the health industry [2]

Core Insights - Zhongkang Technology has launched the "Tiangong No.1 Health Industry AI Application Capability Hub," marking a new phase in the intelligent transformation of the health industry [1][9] - The "Zhuomuniao Medical Model" achieved the top rank in the "Medical Language Understanding" category on the MedBench evaluation platform, highlighting its leading position in the pharmaceutical AI sector [1][2] Group 1: Technological Leadership - The "Zhuomuniao Medical Model" boasts 70 billion parameters, enabling it to deeply analyze vast amounts of medical literature, thus providing precise understanding and extraction of key information [2] - This model addresses the limitations of general AI in the medical field, establishing a solid foundation for deep applications of AI in the health industry [2] Group 2: Industry Value - The "Tiangong No.1 Health Industry AI Application Capability Hub" integrates 18 years of Zhongkang's pharmaceutical industry data and experience, creating a comprehensive AI application ecosystem [3] - The commercial intelligent agent within the hub enhances individual efficiency, allowing medical professionals to generate evidence reports in minutes, increasing productivity by up to 7 times [3] Group 3: Organizational Collaboration - The "Enterprise Growth Workbench" addresses inter-departmental collaboration challenges by providing over 100 intelligent agents that enhance efficiency across the pharmaceutical marketing chain [5][6] - This model breaks down departmental barriers, fostering competitive growth through collaborative evolution [6] Group 4: Strategic Significance - The hub aims to serve as a foundational infrastructure for the intelligent upgrade of the health industry, connecting all segments from research and development to production and distribution [8] - It seeks to redefine operational methods and decision-making processes in the health industry, promoting a new paradigm of human-machine collaboration [8] - Zhongkang Technology is positioned to become a standard setter and connector in the health industry AI application ecosystem, driving innovation and collaboration [8][9]

Core Viewpoint - The recent policy from the State Council to promote AI in healthcare significantly boosts the AI medical industry, indicating a favorable environment for companies like Zhongkang Holdings [1][10]. Group 1: Company Performance - Zhongkang Holdings reported a revenue of 150 million yuan in the first half of the year, a decrease of 7.3% year-on-year, and a net profit of 24.5 million yuan, down 42.1% year-on-year [3]. - The company is undergoing a strategic "deep squat," focusing on building a comprehensive intelligent system in the healthcare sector, which requires substantial upfront investment [3]. - R&D expenses increased by approximately 14.4% year-on-year, indicating a commitment to enhancing computing infrastructure and expanding high-level R&D talent [3]. Group 2: Market Perception and Valuation - Zhongkang Holdings has a market capitalization of only 1.5 billion HKD and a price-to-sales ratio of 3.4, suggesting significant undervaluation [4]. - The market has not fully recognized the company's deep and forward-looking investments in AI, leading to a discrepancy in expected growth potential [5]. Group 3: AI Integration and Business Model - The company integrates AI into its core operations, providing a one-stop AI-driven solution for various clients in the life sciences sector [5]. - Zhongkang has developed advanced AI models and platforms, including the Zhuomuniao medical model and Tian Gong No.1 commercial model, which enhance its service offerings [5][6]. Group 4: Ecosystem and Growth Potential - The company is building a robust "ecological flywheel" effect, where data, models, scenarios, and users interact to create significant value [6][9]. - The accumulation of healthcare data through partnerships allows Zhongkang to train precise AI models, enhancing service efficiency and attracting more users [7]. - The potential for exponential growth exists as the ecological flywheel accelerates, driven by the increasing demand for intelligent solutions in the healthcare sector [9][10].